menu
    • menu
    [{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Safusidenib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Safusidenib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnHeart Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Daiichi Sankyo"}]

    Find Clinical Drug Pipeline Developments & Deals for Safusidenib

    Menu

    Safusidenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AnHeart Therapeutics

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            AnHeart Therapeutics

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Safusidenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Daiichi Sankyo

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AnHeart Therapeutics Announces Initiation of Global Phase 2 Trial Evaluating Safusidenib for IDH1-Mutant Gliom...

                            Details : AB-218 (safusidenib) is a novel, selective, potent, oral mIDH1 inhibitor, which is investigated for the treatment of Grades 2 or 3 recurrent or progressive mutant isocitrate dehydrogenase 1 (mIDH1) glioma, one of the most common types of adult primary br...

                            Brand Name : AB-218

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 07, 2023

                            Lead Product(s) : Safusidenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Daiichi Sankyo

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AnHeart Therapeutics

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            AnHeart Therapeutics

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Safusidenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AnHeart Therapeutics Receives FDA Clearance of IND Application to Initiate Global Phase 2 Study of Safusidenib...

                            Details : Safusidenib (also known as AB-218), is a small molecule mIDH1 inhibitor. Mutations in IDH1 are frequently found in various tumor types such as glioma, cholangiocarcinoma, and chondrosarcoma. Safusidenib has also shown high blood brain barrier penetration...

                            Brand Name : AB-218

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 15, 2022

                            Lead Product(s) : Safusidenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth